Surgical robots have a supply problem: where capacity, not demand, sets the pace

The bottleneck is the factory, not the order book

Across the second-quarter calls in medical and surgical devices, one theme kept coming up: companies have products customers want, and the question is whether they can make and deliver enough of them. Stereotaxis, which sells catheters, says it is supply constrained and working to increase output.¹ Zimmer Biomet says it is struggling to meet demand for its iodine-coated hip devices.⁷

That changes how to read these businesses. When supply is the limit, revenue follows capacity, and every new plant, supplier or inventory build matters more than a fresh marketing push. The companies that have already eased their supply problems are the ones that describe moving deeper into their markets.

Globus Medical is the clearest example. It says improved set deliveries and inventory availability have been a catalyst for deeper market penetration.² Put simply, once the instruments and implants showed up on time, more surgeons used them.

That pattern lines up with our data. Globus Medical leads our score, Zimmer Biomet is second and Stryker is third, and all three spent part of their calls on supply: delivering it, building it, or fixing it.

Stereotaxis: a catheter story that depends on one supplier

$STXS gives the sharpest single read on the theme. The company expects to recognize roughly a $1 million incremental step up in catheter revenue in each of the next couple of quarters.⁵ That is guidance about added output, and it follows directly from management saying the company is working to raise catheter supply.¹

The catch is where that supply comes from. Stereotaxis says its constraint comes from relying on the contract manufacturer Osypka.⁶ A contract manufacturer builds a product for another company, so Stereotaxis's catheter growth depends in large part on how quickly a partner can scale.

For investors, that turns the story into something you can track. If Osypka's output rises as planned, the quarterly step up the company expects becomes visible in reported catheter revenue.⁵ If it stalls, the constraint stays in place, whatever demand looks like.

Zimmer Biomet: a premium product it cannot make enough of

Zimmer Biomet makes hip devices, and its supply problem sits in its most valuable version. The company says it gets a 40% premium when a customer switches from a non-iodine-coated to an iodine-coated hip device.⁸ It also says it is struggling to meet demand for those iodine-coated devices.⁷

That combination matters. A shortage in a low-margin product is a nuisance; a shortage in a product that carries a 40% premium leaves pricing on the table until capacity catches up.⁸ Every added unit of coated-hip supply moves the mix toward the higher-priced device.

The company is building for it. Zimmer Biomet is constructing a new manufacturing plant in Costa Rica to make its supply chain more resilient.³ Management also described its people and culture as becoming a competitive advantage, a softer point but one that matters when a company is opening plants and hiring to run them.⁹ Zimmer Biomet is second in our data, and the plant is the part of its story most closely tied to the supply theme.

Stryker: fixing a disruption while the robot keeps scaling

Stryker sits third in our data and shows both sides of the theme. On the robotics side, its Mako robotic system is installed across 47 countries and has performed over 2.5 million procedures globally.¹⁰ That is an installed base that keeps pulling through instruments and implants.

On the supply side, Stryker had a disruption in its peripheral vascular business and expects to have it managed by the end of the third quarter.⁴ It also reported an elevated backlog as of the end of the second quarter.¹¹ A backlog is orders taken but not yet delivered, so a larger one means product owed to customers rather than demand that went missing.

Stryker also competes in mechanical thrombectomy, the removal of blood clots, with a full suite of products including a clot retriever and a flow retriever.¹² If the disruption clears on the timeline the company expects, the backlog is the place where that recovery should show up first.^4,11

PROCEPT BioRobotics: pricing as a read on demand

PROCEPT BioRobotics offers a useful contrast. It sells a robotic system, HYDROS, which management says is performing well and has been very resilient.¹³ It also says it is selling capital, meaning the robotic systems themselves, at its highest ever pricing, with very good pricing on handpieces, the disposable tools used in each procedure.¹⁴

Record pricing on both the system and the per-procedure tools points to demand that is holding up, the other half of the supply-and-capacity equation. PROCEPT expects to have virtually all of its systems launched under its launch team by year-end.¹⁵ If that holds, the next question for the company moves from rollout toward how quickly those systems turn into procedures.

What to watch next quarter

The useful way to follow this group is to track capacity milestones, not just demand commentary. For Stereotaxis, the test is whether reported catheter revenue shows the step up management expects, and whether it says anything new about Osypka's output.^5,6

For Zimmer Biomet, watch progress on the Costa Rica plant and whether the company still describes coated-hip demand as more than it can supply.^3,7 For Stryker, the marker is whether the peripheral vascular disruption is managed by the end of the third quarter as expected, and what happens to the backlog.^4,11

Globus Medical shows what the far side of a supply fix can look like: better deliveries and inventory, then deeper market penetration.² The companies still working through their constraints are, on their own plans, trying to get there too, and the next round of calls will show who is making progress.